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Abstract
Background: Dengue hemorrhagic fever (DHF) is observed in individuals that have pre-existing heterotypic dengue
antibodies and is associated with increased viral load and high levels of pro-inflammatory cytokines early in infection.
Interestingly, a recent study showed that dengue virus infection in the presence of antibodies resulted in poor stimulation
of Toll-like receptors (TLRs), thereby facilitating virus particle production, and also suggesting that TLRs may contribute to
disease pathogenesis.
Methodology/Principal Findings: We evaluated the expression levels of TLR2, 3, 4 and 9 and the co-stimulatory molecules
CD80 and CD86 by flow cytometry. This was evaluated in monocytes, in myeloid and plasmacytoid dendritic cells (mDCs
and pDCs) from 30 dengue patients with different clinical outcomes and in 20 healthy controls. Increased expression of
TLR3 and TLR9 in DCs of patients with dengue fever (DF) early in infection was detected. In DCs from patients with severe
manifestations, poor stimulation of TLR3 and TLR9 was observed. In addition, we found a lower expression of TLR2 in
patients with DF compared to DHF. Expression levels of TLR4 were not affected. Furthermore, the expression of CD80 and
CD86 was altered in mDCs and CD86 in pDCs of severe dengue cases. We show that interferon alpha production decreased
in the presence of dengue virus after stimulation of PBMCs with the TLR9 agonist (CpG A). This suggests that the virus can
affect the interferon response through this signaling pathway.
Conclusions/Significance: These results show that during dengue disease progression, the expression profile of TLRs
changes depending on the severity of the disease. Changes in TLRs expression could play a central role in DC activation,
thereby influencing the innate immune response.
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Introduction
Dengue is the most widespread mosquito-borne viral disease
worldwide. It is estimated that 50 million dengue infections occur
each year, and that 2.5 billion people are at risk of acquiring
dengue virus (DENV) infection [1]. It is caused by any of the four
distinct, but closely related DENV serotypes (DENV-1 to 4), that
are members of the Flaviviridae family [2]. DENV infection may
lead to a febrile illness known as dengue fever (DF) but can also
result in life-threatening complications defined as dengue hemor-
rhagic fever (DHF) and dengue shock syndrome (DSS) [3].
Clinical and epidemiological studies have revealed that second-
ary infection with a heterotypic serotype is a risk factor for the
development of DHF [4,5]. Furthermore, infants born from
dengue-immune mothers are at risk of acquiring severe dengue
disease during a primary infection [6]. The development of severe
disease has therefore been linked to the presence of pre-existing
antibodies. Although the mechanisms involved in immune
enhanced disease are still poorly understood, multiple in vitro
studies have shown that antibodies promote viral entry and
suppress antiviral responses, allowing a higher production of virus
particles per infected cell [7–9]. The high infected cell mass and
viral load seen early in infection together with an aberrant T cell
response is believed to induce a cytokine storm which causes the
hemorrhagic manifestations.
The first line of defense towards pathogens is mediated by the
innate immune system. Key players in the initiation of the innate
immune response are Toll-like receptors (TLRs). TLRs recognize
invaders through the detection of pathogen-associated molecular
patterns. To date, 10 TLRs have been described in humans, 6 of
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which (TLR2, 3, 4, 7, 8, and 9) are implicated in recognition of
viral components, namely viral nucleic acids and proteins [10].
TLRs are abundantly expressed in monocytes, macrophages and
dendritic cells (DCs) [11,12], the main target cells of DENV, and
trigger antiviral defenses such as the production of interferon and
pro-inflammatory cytokines. Activation of TLR3 and TLR7
inhibits DENV replication in the monocyte cell line U937 and
the human cell line HEK293, respectively [13], indicating that
these TLRs possess antiviral activity towards DENV. Intriguing-
ly, however, when DENV cell entry is facilitated by antibodies,
activation of TLR-negative regulators and down-regulation of
TLR4 and genes associated with TLR signaling, have been
observed in the monocyte cell line THP1 [14]. These results
indicate that immune suppressive mechanisms are activated
through this mode of viral entry. Similar results were found in
peripheral blood mononuclear cells (PBMCs) from patients
experiencing secondary DHF but not DF. Furthermore, and in
line with the above observations, several clinical studies have
indicated that alterations in pro-inflammatory cytokine produc-
tion, as observed in DHF patients, can be attributed to
recognition through TLRs [5]. Taken together, the recognition
and subsequent activation of TLRs may be a contributing factor
in dengue disease pathogenesis. In this study we examined the
expression level of TLR2, 3, 4 and 9 and of the co-stimulatory
molecules CD80 and CD86 in dengue patients experiencing
distinct disease manifestations. TLRs and CD80/CD86 expres-
sion was evaluated in the acute and convalescent phase of the
disease. The expression patterns of the different TLRs were
assessed in monocytes [15,16], plasmacytoid DCs (pDCs) [17–19]
and myeloid DCs (mDCs) [20,21,16]. These cells represent
important targets of DENV infection [22], and are key players in
the innate immune response [23]. Our data indicate that there is
a differential regulation of TLR expression profiles during the
acute phase of DF and DHF.
Materials and Methods
Ethics statement
The protocols for patient enrollment and sample collection were
approved by the Committee of Bioethics Research of the Sede de
Investigacio´n Universitaria, Universidad de Antioquia (Medellı´n,
Colombia), as well as by the informed consent form, according to
the principles expressed in the Declaration of Helsinki. All subjects
read and signed an informed consent (including healthy donors).
When the participant was a minor, the informed consent was
signed by at least one parent.
Study populations and blood samples
Thirty DENV-infected patients, 13 female and 17 male subjects
between 12–72 years of age were enrolled in this study. Twenty
healthy individuals, 10 females and 10 males 13–52 years old, were
included as healthy controls (HCs). All HCs were negative for the
DENV NS1 antigen and DENV IgM/IgG antibodies and had not
been vaccinated against yellow fever virus. Dengue patients were
enrolled from May 2009 to February 2010 in five healthcare
centers located in Turbo and Apartado´, two municipalities of
Antioquia, Colombia.
Thirty ml of peripheral blood (PB) collected in EDTA-
containing tubes. Blood samples were collected three times, on
the 3rd and 5th day after the beginning of symptoms (acute
samples), and 15 days after admission to the hospital (convales-
cence samples). Infection with DENV was confirmed if one of the
following tests was positive, (1) Platelia Dengue NS1 Antigen kit
(Bio-Rad Laboratories, Marnes La Coquette, France), (2) DENV
specific real-time RT-PCR [24], (3) DENV IgM detection by
ELISA UMELISA (Centro de Inmunoensayo, Instituto Pedro
Kourı´, La Habana, Cuba) or (4) virus isolation and propagation in
C6/36 mosquito cells [25]. To determine whether the patient had
a primary or secondary infection, the presence of dengue-specific
IgM/IgG antibodies was evaluated, using the PanBio Dengue Duo
Cassette System (PanBio Ltd, Queensland, Australia). Anti-dengue
IgG levels were determined on days 3, 5 and 15 after the
beginning of symptoms, and if there was no rise in IgG titer over
time it was considered as secondary infection. Dengue cases were
classified as DF or DHF according to the 1997 guidelines of the
World Health Organization (WHO) [3], we applied the old
guidelines since the new WHO guidelines published in 2009 are
more directly focused on clinical practice and are not widely
accepted for use in research [26]. Clinical characterization of DHF
included the following criteria: fever, thrombocytopenia (platelet
counts ,1006103/mm3), hemorrhagic manifestations, positive
tourniquet test, and hemoconcentration (20% changes in hemat-
ocrit value) or ascites as evidenced by plasma leakage. A flow chart
explaining the inclusion/exclusion criteria is depicted in Figure 1.
Flow cytometry
PB samples were used to determine the frequency of mDCs,
pDCs and monocytes and their expression of TLRs. In all patients
and healthy controls the proportion of mDCs, pDCs, and
monocytes among blood mononuclear cells was 0.5% (0.4–1.6%)
0.3% (0.1–1%), and 6% (4–12%), respectively. PB was incubated
with the appropriate antibodies at room temperature for
25 minutes. The whole blood was lysed with lysing Buffer (BD
Biosciences, San Jose, CA) during 10 minutes at room tempera-
ture. Leucocytes were resuspended and washed in PBS containing
0.5% BSA and 0.1% sodium, fixed with 2% formaldehyde and
stored at 4uC until analysis. For staining of intracellular receptors
(TLR3 and TLR9), the cells were treated with fixation
permeabilization buffer (eBiosciences, San Diego. CA) following
Author Summary
Dengue virus (DENV) infections cause a broad spectrum of
clinical manifestations, ranging from self-limited fever to
severe disease, such as dengue hemorrhagic fever (DHF)
that can be fatal. The pathogenesis of severe dengue is
associated with an inadequate immune response charac-
terized by the over-production of cytokines and other
inflammatory components. However, little is known about
the role of the innate immune response in the progression
to hemorrhagic manifestations. TLRs are among the most
important components of innate immunity and are
responsible for initiating a response against a variety of
pathogens, including viruses. Recent studies suggest that
TLRs may contribute to disease pathogenesis. Here we
aimed to explore the role of these receptors in dengue
disease progression. To this end, we examined the
expression of several TLRs and of co-stimulatory molecules
in monocytes and DCs from dengue patients. A link
between TLRs expression and the severity of dengue was
observed: patients with dengue fever express higher levels
of TLR3 and TLR9 than patients with DHF. This could be
crucial for the host defense against dengue virus or
disease progression. In addition, expression of CD80 and
CD86 was altered in DCs of severe dengue cases. We show
that interferon type I production is also altered in vitro
through TLR9. This suggests that dengue virus affects the
interferon response through this signaling pathway.
Toll-like Receptors Expression in Dendritic Cells
PLOS Neglected Tropical Diseases | www.plosntds.org 2 February 2013 | Volume 7 | Issue 2 | e2060
manufacturer’s recommendations. All samples were evaluated
within 2–4 h of staining and 200,000 events were acquired per
tube. Analyses were performed using the BD FACS Dive V6.1.1
(BD Biosciences), and the operating software on the FACS Canto
II flow cytometer. TLR levels were reported as mean fluorescent
intensity (MFI) compared to the isotype control. Logical gating
was used to identify mDC, pDC and monocyte populations. The
acquisition gate (P1) was common for all the populations and was
established based on forward scatter (FSC) and side scatter (SSC)
corresponding to the gate of mononuclear cells (approximately
130,000–170,000 events). For phenotyping of each sub-population
a single tube analysis was performed. The following strategy was
used: mDCs (Lin12/CD11chigh) were gated as P3; Lin1 positive
cells were excluded from the analysis (gate P2). The pDCs (BDCA-
2+/CD123high) were gated as P2. Monocytes were identified as
CD14+ versus side scatters and gated as P2 (Fig. 2A). Each specific
sub-population was plotted as a histogram to show the expression
of TLR2 (Fig. 2B), 3, 4 and 9. The data are presented as overall
MFI for TLR on the TLR+ subset, after subtraction of isotype
staining background. The following monoclonal antibodies were
used: Lineage 1 FITC (anti-CD3, anti-CD14, anti-CD16, anti-
CD19, anti-CD20, and anti-CD56 cocktail), anti-CD123 PE-Cy5,
anti-CD11c PE-Cy5, anti-CD80 PE and anti-CD86 PE (BD
Biosciences, San Jose, CA). Anti-TLR2, 3, 4 and 9 were PE
conjugates (eBiosciences). Anti-BDCA-2 FITC was from Miltenyi
Biotec (Auburn CA). Unstained cells and conjugated isotype
antibodies were used as controls; all of them matched for
concentration with the primary antibodies. All reagents were used
according to manufacturer’s instructions.
Virus stocks and titration
The DENV-2 New Guinea C strain (NGC) was provided by the
Center for Disease Control (CDC, Fort Collins, CO), and
propagated in the C6/36 mosquito cell line. C6/36 cells were
grown in L15 medium (Invitrogen, Carlsbad. CA) supplemented
with 10% heat-inactivated fetal bovine serum, 1% vitamins, 1% L-
glutamine and 1% non-essential amino acids (Sigma-Aldrich
Chemical Co, St. Louis, MO), and incubated at 34uC without
CO2 for 24 h. The cells were inoculated with DENV-2 at 0.01
multiplicity of infection (MOI) and incubated at 34uC for 5–6
days. The supernatants were collected and clarified by centrifu-
gation (1500 g, 10 min). The virus titer was determined by
conventional plaque assay in kidney rhesus monkey cells, (LLC-
MK2), essentially as described [27]. Inactivation of the virus was
achieved by exposure to UV light for 60 min.
Influenza A virus (IAV) strain A/PR8/34 was kindly donated by
Paula Velilla (Immunology Group, Universidad de Antioquia).
Virus titration was performed by limit dilution method, using 96-
well microplates (Nunclon, NY). The virus titer was estimated by
the cytopathogenicity of the cells and expressed as 50% tissue
Figure 1. Flowchart of enrolment, inclusion/exclusion criteria, diagnosis and classification of dengue patients.
doi:10.1371/journal.pntd.0002060.g001
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culture infectious doses/ml (TCID50/ml) of IAV; 1610
4 TCID50/
ml were used for the infection of PBMCs. The supernatant from
IAV-infected PBMCs was used as a positive control to measure
interferon concentration by ELISA (eBioscience).
Preparation and infection of PBMCs
PBMCs were isolated from HCs by density gradient centrifu-
gation using Ficoll-Hypaque (Histopaque 1077, Sigma Aldrich
Chemical Co., St. Louis, MO); all samples were processed within
the first 8 h after collection. PBMCs were cultured at 1.06106
cells/ml in 24-well polystyrene tissue culture plates at 37uC in 5%
CO2, using RPMI 1640 medium (BioWhittaker, Walkersville,
MD) supplemented with 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin/streptomycin (Sigma Aldrich Chemical Co.)
and 1% of L-glutamine (Sigma Aldrich Chemical Co.). Subse-
quently, the cells were challenged with wild-type DENV or UV-
inactivated (iDENV), at a MOI of 5, for 2 h at 37uC in 5% CO2.
The PBMCs were then washed and incubation was continued for
another 24 h in the presence or absence of a TLR agonist: 50 mg/
ml of polyinosinic:polycytidylic acid [poly(I:C)], 10 mg/ml of
lipopolysaccharide (LPS), 5 mg/ml resiquimod (R848) and 5 mM
oligonucleotides with motifs of unmethylated cytosine-phosphate-
guanine (CpG) dinucleotides type A (CpG A; Invivogen), for
TLR3, TLR4, TLR7/8 and TLR9, respectively. To neutralize the
stimulatory effect of CpG ODNs, 5 mM ODN TTAGGG was
used (Invivogen). The supernatants were harvested after 24 h of
culture and the interferon alpha (IFN-a) concentration was
measured by ELISA according to the manufacturer’s protocol
(eBioscience).
Statistical analyses
Statistical comparisons between the HCs and the dengue groups
were performed using the Kruskal-Wallis test, with a confidence
level of 95% followed by Dunn’s multiple comparison test. To
compare TLR expression according the severity of the disease, a
Mann-Whitney test was employed. The critical value for statistical
significance used for the analyses was p,0.05. All the analyses




In this study, 45 patients were enrolled, 30 of which were
positive for DENV infection. From the 30 dengue positive cases,
19 (67%) were classified as DF- and 11 as DHF-patients (Fig. 1),
based on the guidelines of the WHO [3]. The patients were
admitted to the hospital and PB samples were taken on days 3, 5,
and 15 after onset of symptoms. Six patients (26.6%) developed
ascites related to dengue infection; there were neither patients with
DSS nor mortal cases. The demographic and clinical information
of the 30 dengue patients enrolled in this study are summarized in
Table 1.
TLR expression is up-regulated in mDCs and pDCs during
the acute phase of dengue
DCs are not only important target cells of DENV infection; they
also play a central role in the innate antiviral response, through
TLR activation. Therefore, we evaluated the expression levels of
TLR2, TLR3, TLR4 and TLR9 in mDCs, pDCs and monocytes
of dengue patients, and compared them to the HCs. In mDCs of
dengue patients, TLR3, TLR4 and TLR9 reached maximum
expression on day 5 of illness (Fig. 3A). The MFI results showed
that expression of TLR3 in mDCs was significantly higher in
dengue patients than in HCs, on days 3 and 5 of illness (p,0.05
and p,0.01, respectively; Fig. 3A). For TLR4, only at day 5 a
significantly higher expression was observed (Fig. 3A). Expression
of TLR9 in mDCs of dengue patients was significantly increased
(p,0.05) on day 5 of illness compared to those of HCs, while
expression of TLR2 in mDCs did not differ between dengue
patients and HCs (Fig. 3A). Our results also show that on day 15,
the level of expression of all the TLRs tested decreased to levels
similar to those of HCs (Fig. 3A).
Unlike in mDCs, in pDCs of dengue patients, only TLR2
expression was stimulated. The MFI of TLR2 reached maximum
peaks on day 5 of illness. (Fig. 3B). On day 15, TLR2 expression
was similar to that of HCs (Fig. 3B), suggesting that after DENV
infection, TLR2 expression tends to normalize. In pDCs, the
expression of TLR3, 4 and, 9 did not differ between dengue
patients and HCs (Fig. 3B). In monocytes, no differences in TLR
expression levels were detected between dengue patients and HCs
(data not shown). Similar results were obtained when the TLR
frequency was evaluated on the basis of absolute cell counts (data
not shown).
Differential expression of TLR2 in mDCs and pDCs of DF
and DHF patients during the acute phase of infection
The development of DHF is associated with an increased level
of circulating pro-inflammatory cytokines and chemokines [28–
Figure 2. Gating strategy for identification of mDCs, pDCs and monocytes from PB samples and TLR staining. (A) Non duplets
population was fractioned in mDCs as mononuclear cells Lin2 and CD11c High (P3); (pDCs) as CD123+ BDCA2+ (P2) and monocytes as CD14+ (P2) . (B)
Representative examples of TLR2 expression in mDCs, pDCs, and monocytes. HC indicates healthy control and DF denotes for dengue fever.
doi:10.1371/journal.pntd.0002060.g002
Table 1. Demographic and clinical characteristics of 30
individuals with diagnosis of dengue and 20 healthy controls.
Controls DF* DHF*
n=20 n=19 n=11
Age, yr, mean 6SD 32.61(16.41) 30.94(18.24) 33.09(12.56)
Gender
Male 10 11 6
Female 10 8 5




Spontaneous hemorrhage 4(21.05) 8(72.72)
Positive tourniquet result 5(26.31) 9(81.81)
Units specified in parenthesis are percentages; otherwise data are numbers.
(DF)* =Dengue fever; (DHF)* =Dengue Hemorrhagic fever;
Thrombocytopenia* = Platelet counts ,100000/mm3;
Hemoconcentration* =Hematocrit level rising $20%; Ascites* = accumulation
of fluid in the peritoneal cavity confirmed by abdominal ultrasound;
Spontaneous hemorrhage = nose bleeding, gastrointestinal bleeding, ocular
bleeding, and/or bleeding gums; Positive tourniquet = petechiae of $20 spots
in a 2.5-cm2 area on the forearm after application of pressure at the midpoint
between systolic and diastolic pressure for 5 min using a sphygmomanometer.
doi:10.1371/journal.pntd.0002060.t001
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30], and several in vitro studies indicate that TLRs may contribute
to this phenomenon [5,31]. Therefore, we compared the
expression profiles of TLR2 and TLR4 in mDCs, pDCs and
monocytes of patients with DF and DHF on different days of
disease to those of HCs. Similar TLR2 and TLR4 expression
levels were detected in monocytes of DF, DHF patients and HCs
(data not shown). In contrast, there was a modulation in TLR2
expression in DCs of DF and DHF patients. On day 3 of illness,
DF patients presented significantly lower TLR2 expression in
mDCs, compared to HCs and DHF patients (p,0.05; Fig. 4A).
On days 5 and 15, the level of TLR2 expression was similar in
patients with DF and DHF. In pDCs of DHF patients, a significant
increase in TLR2 expression was seen on day 3 of illness,
compared to HCs (p,0.05; Fig. 4B). This increase reached a
maximum on day 5 of acute infection (p,0.001). No differences
were found in TLR4 expression levels in mDCs (data not shown).
TLR3 and TLR9 expression is higher in DCs of DF than in
those of DHF patients
The effect of DENV on intracellular TLR expression was
evaluated in cell lines and in animal models [32,33]; however, the
effect of DENV infection on the modulation of intracellular TLR
expression in DCs of patients with DF or DHF has not been
reported. The results show that on day 5 after the beginning of
symptoms, mDCs of DF patients had a higher MFI for TLR3 and
TLR9 than mDCs of DHF patients (p,0.05) and HCs (p,0.001
and p,0.01), respectively; Fig. 5A and B). On day 3 of illness,
mDCs from DF or DHF showed a higher MFI for TLR3 and
TLR9 compared to those of HCs (Fig. 5A). In the convalescent
phase, the expression levels of TLR3 and TLR9 decreased to
similar levels as in HCs. The MFI results for TLR9 in pDCs of DF
patients showed higher expression levels on day 3 of illness
compared to those of DHF patients (p,0.05; Fig. 5A). Taken
together, our results are consistent with recently published in vitro
data [13,32,33] and suggest that the increase in TLR3 and TLR9
expression in DF patients could act as an antiviral factor.
Down-modulation of CD80/CD86 in mDCs of DHF
patients
Infection of mDCs with DENV has been reported to induce DC
maturation and activation, albeit to lower levels than observed in
uninfected DCs [34,35]. Since the effect of DENV on DC
maturation is unclear in vivo, we assessed here the maturation state
of the mDCs and pDCs by examining the expression profile of the
co-stimulatory molecules CD80/CD86 in DF and DHF patients.
Because the co-stimulatory molecule CD80 appears to be
expressed in resting unstimulated mDCs [36], we quantified the
expression level of CD80 in mDCs of patients with DF and DHF
and compared it with the expression in mDCs of HCs. Analysis of
the MFI showed that the mDCs of DHF patients express
significantly lower levels of CD80 (p,0.05) and CD86
(p,0.001), when compared to HCs (Fig. 6A and 6B). Likewise,
in pDCs, a significant decrease in the expression level of CD86 was
seen in patients with DF and DHF (p,0.05 and p,0.01,
respectively), compared to HCs. No differences were found in
the expression of CD80 in pDCs (data not shown). Taken
together, we observed low expression of TLR3, TLR9, CD80/
CD86 in DCs of DHF patients.
Figure 3. Increased expression of TLRs in mDCs and pDCs of dengue-infected patients. Expression profile of TLR2, 3, 4 and 9 in mDCs (A)
and pDCs (B) of dengue patients isolated at different times after the onset of disease symptoms (day 3, 5 and 15) (n= 30) and of healthy controls
(n=20). The evaluation of TLR expression was performed by flow cytometry based on mean fluorescence intensity (MFI) analysis. Data are presented
as the median and 25–75 interquartile ranges Statistical analysis was performed by using the Kruskal-Wallis test followed by the Dunn’s Multiple
comparisons Test. *p,0.05, ** p,0.01 and ***p,0.001.
doi:10.1371/journal.pntd.0002060.g003
Figure 4. Increased TLR2 expression in pDCs of patients with severe disease. Analysis of TLR2 expression by flow cytometry of PB mDCs (A)
and pDCs (B) in DF patients (n = 19) and DHF patients (n = 11) at different times after the onset of symptoms (days 3, 5 and 15). Data are presented as
the median and 25–75 interquartile ranges. Statistical analysis was performed by the Mann Withney test.*p,0.05, ** p,0.01 and ***p,0.001.
doi:10.1371/journal.pntd.0002060.g004
Toll-like Receptors Expression in Dendritic Cells
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Type I IFN production through TLR9 is impaired in DENV
infection of PBMCs in vitro
It is known that DENV is a weak inducer of type I IFN
production after infection of human DCs. Several possible
mechanisms have already been proposed to explain this observation
[37–39]. The differential expression profiles of TLR3 and TLR9 in
DF and DHF patients presented here may also influence type I IFN
secretion. However, whether recognition of viral components by
TLRs triggers IFN production in DENV-infected cells, or, whether
DENV infection affects the function of TLRs is largely unclear. To
Figure 5. TLR3 and TLR9 in mDCs and TLR9 in pDCs have different expression levels depending on disease severity. Expression
profile of TLR2 and TLR9 in mDCs (A and B) and pDCs (C) of dengue patients isolated at different times after the onset of disease symptoms (day 3, 5
and 15) (n= 30) and of healthy controls (n= 20). The evaluation of TLR expression was performed by flow cytometry based on mean fluorescence
intensity (MFI) analysis. Data are presented as the median and 25–75 interquartile ranges Statistical analysis was performed by using the Kruskal-
Wallis test followed by the Dunn’s Multiple comparisons Test. *p,0.05, ** p,0.01 and ***p,0.001.
doi:10.1371/journal.pntd.0002060.g005
Figure 6. Expression of the co-stimulatory molecules CD80 and CD86 is affected in mDCs of DHF patients. Expression of CD80 (A) and
CD86 (B) was evaluated by flow cytometry based on the FMI analysis in mDCs and pDCs (C) of DF and DHF patients on day 3 of illness and compared
to that of healthy controls (HC). Data are presented as the median and the statistical analysis of the expression of CD80 and CD86 was performed by
the Mann Withney test.*p,0.05, ** p,0.01 and ***p,0.001.
doi:10.1371/journal.pntd.0002060.g006
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expand our knowledge on this subject, we tested the ability of
PBMCs to respond to the TLR3, TLR4, TLR7/8 and TLR9
ligands, and to trigger the IFN-a pathway. To this end, cells were
infected with wild-type DENV or inactivated DENV (iDENV) and
2 h post-addition of the virus, the specific TLR ligands were added
to the cells. We decided to uses PBMCs for these studies to mimic
natural infection thereby allowing cross talking between cell subsets.
PBMCs treated with the TLR3, TLR7/8 and TLR9 agonists, and
challenged with DENV, showed variable but enhanced IFN-a
production when compared to of non-treated cells, except for the
TLR4 agonist LPS, which produced similar levels of IFN-a as the
control (Fig. 7). PBMCs infected with DENV in the presence of the
TLR3, and 7/8 agonists further stimulated IFN-a production
(p,0.05). The observation that iDENV produces a more robust
IFN-a response than wild-type DENV is in line with prior published
data indicating that the nonstructural proteins, NS2B, NS4B and
NS5 are responsible for inhibition of type I IFN production [37–39].
Interestingly, DENV infection of PBMCs in the presence of the
TLR9 agonist CpG led to a significant decrease of IFN-a expression
(p,0.05), compared to PBMCs treated with CpG A only. To
investigate the potential effect of TLR9 in more detail, we next
infected PBMCs in the presence of CpG A and the TLR9
antagonist TTAGGG ODN, which neutralize the stimulatory effect
of CpG A. The ligands were added 2 hours post-infection with
DENV. The addition of antagonist indeed decreased IFN-a
production when compared to cells treated with agonist only
(p,0.05). Interestingly, a stronger reduction in IFN-a production
was observed in the presence of the virus (Fig. 7; p,0.01) which may
suggest a combined effect between DENV and the antagonist, in the
IFN-a reduction. However, additional experiments are required to
confirm this hypothesis.
Discussion
An immune response with loss in the homeostasis of cytokine
secretion has been proposed as the central event in the
development of DHF [40]. TLRs are important initiators of
cytokine production and in this report we show that DENV can
modulate/alter TLRs expression in DCs. We observed increased
expression level of TLR3 and TLR9 in mDCs, and of TLR2 in
pDCs, during the acute phase (days 3–5 after onset of symptoms)
of DENV infection. When dengue patients were classified
according the clinical outcome, a higher expression level of
TLR2 was seen in DHF patients when compared to DF patients.
In contrast, mDCs of DF patients expressed higher levels of TLR3
and TLR9 than those of DHF patients, especially on day 5 of
illness. In pDCs, this difference was also observed for TLR9 on
day 3 of illness.
The mDCs and pDCs are both important players of the innate
immune system, but vary with respect to their origin, phenotype
and functional features [41,42]. Previous studies have also
indicated that these cells differ in permissiveness to DENV
infection. Whereas mDCs are readily infected with DENV, pDCs
are essentially non-permissive to infection [43]. Interestingly, we
observed changes in TLR expression in both mDCs and pDCs
during the early acute phase of illness. TLR3 expression was
increased in mDCs, and this is likely related to infection of these
cells since TLR3 is known to recognize dsRNAs [44]. Cell surface-
expressed TLR2 was up-regulated in pDCs, presumably due to
sensing of the virus at the cell surface. Indeed, even though pDCs
do not support a full replicative cycle of DENV, these cells do
respond to infection since phenotypic and functional changes have
been described upon addition of DENV to these cells [41]. This
phenomenon has also been previously reported for HIV-1, where
in vitro studies showed up-regulation of TLR2 and TLR4 in pDCs
[17,18].
Notably, we also found an up-regulation of TLR9 in mDCs.
Basal expression of TLR9 has not been previously reported in
mDCs, but a recent study showed that mDCs respond to the
TLR9 agonists CpG A and CpG B thereby increasing the
expression levels of CD80 and of human leukocyte antigen (HLA-
DR9) molecules on the cell surface [16]. These findings suggest
that the expression of TLR9 can be enhanced after stimulation
with its agonist. We show here that IFN-a production was
significantly affected in PBMCs exposed to DENV in the presence
of the TLR9-agonist, which may suggest that TLR9 responds to
Figure 7. IFN-a production by PBMCs in response to TLR9 ligand is impaired by DENV infection. PBMCs from healthy controls were
challenge with wild type DENV or iDENV at a MOI of 5 and then stimulated with agonists for TLR3 (poly:IC), TLR4 (LPS), TLR7 and TLR8 (R848) and TLR9
(CpG A). The production of IFN-a was measured by ELISA a 24 h post-stimulation. The antagonist of TLR9 (TTAGGG ODN) was used to neutralize the
stimulatory effect of GpG A. The supernatant from C6/36 cells were used as mock and Influenza virus was used as a positive control for IFN-a
production.. Data are presented as the mean of values of at least two independent experiments performed in triplicate; error bars indicate standard
deviation. Statistical comparisons among groups were carried out using the Kruskal-Wallis test comparing between groups. *p,0.05 and** p,0.01.
doi:10.1371/journal.pntd.0002060.g007
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DENV infection. However, how TLR9 is activated in DENV
infection is unclear, as TLR9 is known to recognize pathogen-
associated DNA [19,45,46]. One could speculate that the
increased TLR9 expression is due to cross-talk between different
receptors or adaptor proteins from different signal pathways as has
been described to occur in a pro-inflammatory environment [47].
Monocytes have also been reported to represent target cells of
DENV replication [48]. Moreover, Azeredo et al. [31] showed an
increase of TLR2 expression in monocyte CD14+ of dengue-
infected patients. Subsequent in vitro studies revealed an increased
frequency of TLR2 in pro-inflammatory monocytes (CD14+ and
CD16+) and it was proposed that overexpression of TLR2 in
CD16+ cells could contribute to DHF. We also assessed TLR2/
TLR4 expression in monocytes but no effect of DENV infection
on TLR2 and TLR4 expression was detected. This discrepancy is
probably related to differences in the analysis and classification of
the cell populations.
TLR3 is specifically up-regulated in mDCs in patients with
acute DF since no TLR3 up-regulation is seen in patients that
develop DHF. Previously, Tsai and co-workers [13] reported that
TLR3 induces an anti-dengue response in HEK293 cells.
Furthermore, there is evidence that the type I IFN response
initiated by TLR3 contributes to the elimination of Hepatitis C
virus [49]. Based on the above observations, we postulate that
TLR3 is associated with antiviral responses against DENV,
promoting the production of pro-inflammatory cytokines and type
I IFN. This inhibition of DENV could prevent the development of
severe manifestations. Indeed, and in line with our results, a recent
report showed down-regulation of TLR3, TLR4 and TLR7/8 in
PMBCs of patients experiencing secondary DHF but not in
patients expressing DF [14].
TLR2 expression was up-regulated in pDCs and mDCs of DHF
patients but not of DF patients. Recent studies suggest that TLR2
is an important promoter of pro-inflammatory cytokine release,
(reviewed in [46,47]). Increased pro-inflammatory cytokine
production is one of the hallmarks of severe disease [50,51].
Therefore we postulate that individuals with a higher response to
DENV through TLR2 may be more likely to develop severe
manifestations, whereas patients who express TLR3 and TLR9,
may have some degree of protection and may probably be less
likely to develop DHF.
TLRs not only promote cytokine release; they also promote the
up-regulation of co-stimulatory molecules such as CD80 and
CD86 to favor cell maturation and efficient antigen presentation
to T cells [52]. We found that mDCs of DHF patients have lower
expression levels of CD80 and CD86 than HCs suggesting
inefficient maturation of mDCs in these patients. This may be
explained by the low TLR3 and TLR9 expression level in patients
with DF or DHF. In pDCs, a significant down-regulation of CD86
was observed in both DF and DHF patients. This could have
important consequences on the development of a specific immune
response able to induce memory T cells to control future infection.
This hypothesis is supported by the observation of lower CD80/
CD86 expression levels in DHF patients, compared to DF patients
(in mDCs) and HCs (in DCs). Libraty et al. [34] reported lower
expression of CD80 and CD86 in DCs in DENV infection in vitro.
Sun et al. (2009) observed that in purified pDCs and mDCs the
presence of the virus promotes the expression of CD80 and CD86
in mDCs but not in pDCs suggesting that DENV can down
regulate the co-stimulatory molecules CD80 and CD86 [43].
However, further studies are required to elucidate the mechanisms
involved in this phenomenon.
In conclusion, the differential expression of TLRs in dengue
may influence the clinical outcome of the disease. Future research
is necessary to fully understand the participation of the innate
immune response in dengue pathogenesis and to assess the
possibility of using TLR agonists as vaccine adjuvants in dengue
vaccines.
Acknowledgments
We are grateful to the Institute of Tropical Medicine in Apartado´
Colombia, for help in the recruitment of dengue patients and the collection
of samples; we also thank all the patients who participated in this study.
The authors thank Anne-Lise Haenni and Izabela Rodenhuis for reading
the manuscript and constructive and valuable comments.
Author Contributions
Conceived and designed the experiments: ST JCH SUI. Performed the
experiments: ST JCH DG SUI. Analyzed the data: ST JCH MA MR JMS
SUI. Contributed reagents/materials/analysis tools: MA MR JMS SUI.
Wrote the paper: ST JCH JMS SUI. Patients recruitment: MA.
References
1. WHO (2009) Dengue and Dengue Hemorrhagic Fever. World Health
Organization.
2. Lindenbach BD, Rice CM (2003) Molecular biology of flaviviruses. Adv Virus
Res 59:23–61.
3. WHO (1997) Dengue Hemorrhagic fever: Diagnosis, treatment, prevention and
control. World Health Organization.
4. Halstead SB, Nimmannitya S, Cohen SN (1970) Observations related to
pathogenesis of dengue hemorrhagic fever IV. Relation of disease severity to
antibody response and virus recovered. Yale J Biol MEd 42:311–
328.
5. de Kruif MD, Setiati TE, Mairuhu AT, Koraka P, Aberson HA, et al. (2008)
Differential gene expression changes in children with severe dengue virus
infections. PLoS Negl Trop Dis 2:e215.
6. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, et al. (2008) Dengue
in Vietnamese infants-results of infection-enhancement assays correlate with age-
related disease epidemiology, and cellular immune responses correlate with
disease severity. J Infect Dis 198:516–524.
7. Boonnak K, Dambach KM, Donofrio GC, Tassaneetrithep T, Marovich MA
(2011) Cell Type Specificity and Host Genetic Polymorphisms Influence
Antibody-Dependent Enhancement of Dengue Virus Infection. J Virol
85:1671–1683
8. van der Schaar HM, Wilschut JC, Smit JM (2009) Role of antibodies in
controlling dengue virus infection. Immunobiology 214:613–629.
9. Vaughn DW (2000) Dengue Viremia Titer, Antibody Response Pattern, and
Virus Serotype Correlate with Disease Severity. J Infect Dis 181:2–9.
10. Takeda K, Akira S (2007) Toll-like receptors. Curr Protoc Immunol. Chapter
14: Unit 14.12.
11. Zarember KA, Godowski PJ (2002) Tissue Expression of Human Toll-Like
Receptors and Differential Regulation of Toll-Like Receptor mRNAs in
Leukocytes in Response to Microbes, Their Products, and Cytokines.
J Immunol 168:554–561.
12. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A (2001)
Specialization and complementarity in microbial molecule recognition by
human myeloid and plasmacytoid dendritic cells. Eur J Immunol 11:3388–3393.
13. Tsai YT, Chang SY, Lee CN, Kao CL (2009) Human TLR3 recognizes dengue
virus and modulates viral replication in vitro. Cell Microbiol 11:604–615.
14. Modhiran N, Kalayanarooj S, Ubol S (2010) Subversion of innate defenses by
the interplay between DENV and pre-existing enhancing antibodies: TLRs
signaling collapse. PLoS Negl Trop Dis 4:e924.
15. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdo¨rfer B, et al. (2002)
Molecular and Structural Immunology: Quantitative Expression of Toll-Like
Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood
Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. J Immunol
168:4531–4537.
16. Nguyen M, Leuridan E, Zhang T, De Wit D, Willems F, et al. (2010) Acquisition
of Adult-Like TLR4 and TLR9 Responses during the First Year of Life. PLoS
ONE 5: e10407.
17. Hernandez JC, Arteaga J, Paul S, Kumar A, Latz E, et al. (2011) Up-Regulation
of TLR2 and TLR4 in Dendritic Cells in Response to HIV Type 1 and
Coinfection with Opportunistic Pathogens. AIDS Res Hum Retroviruses
10:1099–1109.
18. Hernandez JC, Stevenson M, Latz E, Urcuqui-Inchima S (2012) HIV Type 1
Infection Up-Regulates TLR2 and TLR4 Expression and Function in Vivo and in
Vitro. AIDS Res Hum Retroviruses 10:1313–28.
Toll-like Receptors Expression in Dendritic Cells
PLOS Neglected Tropical Diseases | www.plosntds.org 10 February 2013 | Volume 7 | Issue 2 | e2060
19. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like
receptor recognizes bacterial DNA. Nature 408:740–745.
20. Kadowaki N, Ho S, Antonenko S, De Waal Malefyt R, Kastelein RA, et al.
(2001) Subsets of Human Dendritic Cell Precursors Express Different Toll-like
Receptors and Respond to Different Microbial Antigens. J Exp Med 194:863–
870.
21. Perrot I, Deauvieau F, Massacrier C, Hughes N, Garrone P, Durand I, et al.
(2010) TLR3 and Rig-Like Receptor on Myeloid Dendritic Cells and Rig-Like
Receptor on Human NK Cells Are Both Mandatory for Production of IFN-c in
Response to Double-Stranded RNA. J Immunol 185:2080–2088.
22. Marovich M, Grouard-Vogel G, Louder M, Eller M, Sun W, et al. (2001)
Human dendritic cells as targets of dengue virus infection. J Investig Dermatol
Symp Proc 6:219–224.
23. Cella M, Sallusto F and Lanzavecchia A (1997) Origin, maturation and antigen
presenting function of dendritic cells. Curr Opin Immunol 9:10–16.
24. Chutinimitkul S, Payungporn S, Theamboonlers A, Poovorawan Y J (2005)
Dengue typing assay based on real-time PCR using SYBR Green I. Virol
Methods. 129:8–15.
25. Singh KR, Paul SD (1969) Isolation of dengue viruses in Aedes albopictus cell
cultures. Bull World Health Organ 40: 982–983.
26. Srikiatkhachorn A, Rothman AL, Gibbons RV, Sittisombut N, Malasit P, et al.
(2011) Dengue-How Best to Classify It. Clin Infect Dis 53:563–7
27. Alvarez M, Rodriguez-Roche R, Bernardo L, Morier L, Guzman MG (2005)
Improved Dengue Virus Plaque Formation on BHK21 and LLCMK2 Cells:
Evaluation of Some factors. Dengue Bulletin 29:49–57.
28. Gagnon SJ, Mori M, Kurane I, Green S, Vaughn DW, et al. (2002) Cytokine
gene-expression and protein production in peripheral blood mononuclear cells
of children with acute dengue virus infections. J Med Virol 67:41–46.
29. Chang DM, Shaio MF (1994) Production of interleukin-1 (IL-1) and IL-1
inhibitor by human monocytes exposed to dengue virus. J Infect Dis 170:811–
817.
30. Lee YR, Liu MT, Lei HY, Liu CC, Wu JM, et al. (2006) MCP-1, a highly
expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome
patients, may cause permeability change, possibly through reduced tight
junctions of vascular endothelium cells. J Gen Virol 87:3623–3630.
31. Azeredo EL, Neves-Souza PC, Alvarenga AR, Reis SR, Torrentes-Carvalho A,
et al. (2010) Differential regulation of toll-like receptor-2, toll-like receptor-4,
CD16 and human leucocyte antigen-DR on peripheral blood monocytes during
mild and severe dengue fever. Immunology 130: 202–216.
32. Nasirudeen AM, Wong HH, Thien P, Xu S, Lam KP, et al. (2011) RIG-I,
MDA5 and TLR3 synergistically play an important role in restriction of dengue
virus infection. PLoS Negl Trop Dis 5:e926. doi: 10.1371/jour-
nal.pntd.0000926.
33. Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW, et al. (2006) Flavivirus
activation of plasmacytoid dendritic cells delineates key elements of TLR7
signaling beyond endosomal recognition. J Immunol 177:7114–7121.
34. Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA (2001)
Human dendritic cells are activated by dengue virus infection: enhancement by
gamma interferon and implications for disease pathogenesis. J Virol 75:3501–
3508.
35. Palmer DR, Sun P, Celluzzi C, Bisbing J, Pang S, et al. (2005) Differential effects
of dengue virus on infected and bystander dendritic cells. J Virol 79:2432–2439.
36. Velilla PA, Montoya CJ, Hoyos A, Moreno ME, Chougnet C, Rugeles MT
(2008) Effect of intrauterine HIV-1 exposure on the frequency and function of
uninfected newborns’ dendritic cells. Clin Immunol 3:243–50
37. Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, Ashou J, Ayllon
J, et al. (2010) Inhibition of the Type I Interferon Response in Human Dendritic
Cells by Dengue Virus Infection Requires a Catalytically Active NS2B3
Complex. J Virol 84: 9760–74.
38. Mun˜oz-Jorda´n JL, Sa´nchez-Burgos GG, Lauret-Rolle M, Garcı´a-Sastre A
(2003) Inhibition of interferon signaling by dengue virus. Proc Natl Acad
Sci U S A 24:14333–38.
39. Mazzon M, Jones M, Davidson A, Chain B, Jacobs M (2009) Dengue virus NS5
inhibits interferon-alpha signaling by blocking signal transducer and activator of
transcription 2 phosphorylation. J Infect Dis 200:1261–70.
40. Pang T, Cardosa MJ, Guzman MG (2007) Of cascades and perfect storms: the
immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome
(DHF/DSS). Immunol Cell Biol 85:43–45.
41. Steinman RM, Cohn ZA (1974) Identification of a novel cell type in peripheral
lymphoid organs of mice II. Functional properties in vitro. J Exp Med 139:380–
397.
42. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, et
al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science
315:107–111.
43. Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, et al. (2009)
Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic
cells after infection with dengue virus. Virology 383:207–215.
44. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of
double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.
Nature 413:732–738.
45. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu
Rev Immunol 20:709–760.
46. Marshall JD, Heeke DS, Gesner ML, Livingston B, Van Nest G (2007) Negative
regulation of TLR9-mediated IFN-a induction by a small-molecule, synthetic
TLR7 ligand. J Leukocyte Biol 82:1–12.
47. Yoshida H, Jono H, Kai H, Li JD (2005) The Tumor Supressor Cylindromatosis
(CYLD) Acts as a Negative Regulator for Toll-like Receptor 2 Signaling via
Negative Cross-talk with TRAF6 and TRAF7. J Biol Chem 280:41111–41121.
48. Sun P, Bauza K, Pal S, Liang Z, Wu SJ, (2011) Infection and activation of
human peripheral blood monocytes by dengue viruses through the mechanism
of antibody-dependent enhancement. Virol 421:245–252.
49. Kanda T, Steele R, Ray R, Ray RB (2007) Hepatitis C virus infection induces
the beta interferon signaling pathway in immortalized human hepatocytes.
J Virol 81:12375–12381.
50. Suharti C, van Gorp EC, Dolmans WM, Setiati TE, Hack CE, et al (2003)
Cytokine patterns during dengue shock syndrome. Eur Cytokine Netw 14:172–
177.
51. Mangada MM, Rothman AL (2005) Altered cytokine responses of dengue
specific CD4+ T cells to heterologous serotypes J immunol 175:2676–2683.
52. Akira S (2001) Toll-like receptors: critical proteins linking innate and acquired
immunity. Nature 2:675–680.
Toll-like Receptors Expression in Dendritic Cells
PLOS Neglected Tropical Diseases | www.plosntds.org 11 February 2013 | Volume 7 | Issue 2 | e2060
